div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=bc-2016-6-20-for-the-oncotype-dx-assay-is-generally-subject-to-the-regulationshtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: BC Cancer · 2016 6 20 · for the Oncotype DX assay is generally subject to the regulations applicable in the patients country of residence if no reimbursement or cost coverage loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader036vdocumentsusreader036viewer2022062607604744442de1a32a10479299html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=bc-2016-6-20-for-the-oncotype-dx-assay-is-generally-subject-to-the-regulationshtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: BC Cancer · 2016 6 20 · for the Oncotype DX assay is generally subject to the regulations applicable in the patients country of residence if no reimbursement or cost coverage loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader036vdocumentsusreader036viewer2022062607604744442de1a32a10479299html5thumbnails2jpg width=140 height=200 divdiv
